false
0001534525
0001534525
2024-02-12
2024-02-12
0001534525
XBIO:CommonStock0.001ParValuePerShareMember
2024-02-12
2024-02-12
0001534525
XBIO:PurchaseWarrantsMember
2024-02-12
2024-02-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM
8-K
________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of TheSecurities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 12, 2024
________________________
Xenetic Biosciences,Inc.
(Exact name of registrant as specified in charter)
Nevada 001-37937 45-2952962
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
945 Concord Street
Framingham 01701
,
Massachusetts
(Address of principal executive offices) (Zip Code)
(781)
778-7720
(Registrant's telephone number, includingarea code)
Not Applicable
(Former name or former address, if changed sincelast report)
Check the appropriate box below if theForm 8-K is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (
see
General Instruction A.2. below):
Written communicationspursuant to Rule 425 under the Securities Act (17 CFR
230.425)
Soliciting materialpursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencementcommunications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
Pre-commencementcommunications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per share XBIO The Nasdaq Stock Market
Purchase Warrants XBIOW TheNasdaq Stock Market
Indicate by check mark whether the registrantis an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR (s)230.405) or Rule
12b-2 of the SecuritiesExchange Act of 1934 (17 CFR (s)240.12b-2).
Emerging growth company
If an emerging growth company, indicate by checkmark if the registrant has
elected not to use the extended transition period for complying with any new
or revised financial accountingstandards provided pursuant to Section 13(a) of
the Exchange Act.
Item 7.01. Regulation FD Disclosure.
On February 12, 2024, Xenetic Biosciences, Inc.(the "Company"), posted a
Virtual Investor event video with the Company's Chief Scientific Officer,
Curis Lockshin,PhD., discussing preclinical data from the Company's DNase I
oncology platform.
A link to the video may be found at
https://www.virtualinvestorco.com/wtm-xbio-8k
and is incorporated herein by reference.
The video link is furnished pursuant to this Item7.01 and shall not be deemed
filed in this or any other filing of the Company with the Securities and
Exchange Commission, unless expresslyincorporated by specific reference in any
such filing.
2
SIGNATURES
Pursuant to the requirementsof the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereuntoduly authorized.
XENETIC BIOSCIENCES, INC.
By:
/s/ James Parslow
Date: February 12, 2024 Name: James Parslow
Title: Chief Financial Officer
3
{graphic omitted}
{graphic omitted}